Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests 21 new effective treatments and one drug that increases death risk
Loucera et al.
, Real-world evidence with a retrospective cohort of 15,968 Andalusian COVID-19 hospitalized patients suggests..
, medRxiv, doi:10.1101/2022.08.14.22278751 (Preprint)
Retrospective 15,968 COVID-19 hospitalized patients in Spain, showing lower mortality with existing use of several medications including metformin, HCQ, aspirin, vitamin D, vitamin C, and budesonide.
risk of death, 28.3% lower, HR 0.72, p = 0.002, treatment 840, control 15,128, Cox proportional hazards, day 30.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Loucera et al., 16 Aug 2022, retrospective, Spain, preprint, 8 authors, study period January 2020 - November 2020.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.08.14.22278751; this version posted August 16, 2022. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in
It is made available under a CC-BY-NC-ND 4.0 International license .
Real-world evidence with a retrospective cohort of 15,968
Andalusian COVID-19 hospitalized patients suggests 21 new
effective treatments and one drug that increases death risk.
Carlos Loucera1,2, Rosario Carmona1,2,3, Marina Esteban-Medina1,2, Gerrit Bostelmann1, Dolores
Muñoyerro-Muñiz4, Román Villegas4, María Peña-Chilet1,2,3, Joaquin Dopazo1,2,3,5,*
Computational Medicine Platform, Andalusian Public Foundation Progress and Health-FPS,
Sevilla, 41013, Spain;
Institute of Biomedicine of Seville, IBiS, University Hospital Virgen del Rocío/CSIC/University of
Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER). FPS. Hospital
Virgen del Rocio. 41013. Sevilla. Spain
Subdirección Técnica Asesora de Gestión de la Información. Servicio Andaluz de Salud. 41071,
FPS/ELIXIR-ES, Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013.
Despite the extensive vaccination campaigns in many countries, COVID-19 is still a major
worldwide health problem because of its associated morbidity and mortality. Therefore, finding
efficient treatments as fast as possible is a pressing need. Drug repurposing constitutes a
convenient alternative when the need for new drugs in an unexpected medical scenario is
urgent, as is the case with COVID-19. Using data from a central registry of electronic health
records (the Andalusian Population Health Database, BPS), the effect of prior consumption of
drugs for other indications previous to the hospitalization with respect to patient survival was
studied on a retrospective cohort of 15,968 individuals, comprising all COVID-19 patients
hospitalized in Andalusia between January and November 2020. Covariate-adjusted hazard
ratios and analysis of lymphocyte progression curves support a significant association between
consumption of 21 different drugs and better patient survival. Contrarily, one drug, furosemide,
displayed a significant increase in patient mortality.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.